罗欣药业(002793) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥2,177,073,849.50, representing a 24.89% increase compared to the same period last year[3]. - Net profit attributable to shareholders decreased by 48.07% to ¥81,679,473.74, down from ¥157,400,135.37 in Q1 2021[3]. - Basic earnings per share fell by 45.45% to ¥0.06, down from ¥0.11 in the same quarter last year[3]. - The net profit for the first quarter of 2022 was approximately ¥85.35 million, a decrease of 47.3% compared to ¥161.65 million in the same period last year[34]. - The net profit attributable to the parent company was approximately ¥81.68 million, down from ¥157.30 million, representing a decline of 48.0% year-over-year[34]. - The total comprehensive income for the first quarter was approximately ¥78.52 million, compared to ¥161.28 million in the previous year, reflecting a decrease of 51.3%[34]. Cash Flow and Assets - The net cash flow from operating activities was negative at -¥794,046,525.88, a decline of 219.89% compared to the previous year[3]. - Cash flow from operating activities showed a net outflow of approximately ¥794.05 million, worsening from a net outflow of ¥248.23 million in the same period last year[36]. - Cash inflow from operating activities totaled approximately ¥1.27 billion, down 25.2% from ¥1.70 billion in the previous year[36]. - The company reported cash and cash equivalents at the end of the period of approximately ¥853.54 million, a decrease from ¥920.86 million at the end of the previous year[37]. - The company experienced a net cash outflow from investing activities of approximately ¥101.31 million, compared to a net outflow of ¥91.84 million in the previous year[37]. - The company's total assets increased by 5.90% to ¥10,056,682,341.40 as of the end of Q1 2022[3]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,396[11]. - Shandong Luoxin Holdings Co., Ltd. holds 35.45% of shares, totaling 518,843,206 shares, all of which are pledged[11]. - Karamay Yuzhi Equity Investment Management Partnership holds 9.62% of shares, totaling 140,754,819 shares, all of which are pledged[11]. - Fang Xiubao, an individual shareholder, holds 6.85% of shares, totaling 100,294,266 shares, with no restrictions[11]. - The top 10 shareholders include entities with significant pledged shares, indicating potential liquidity risks[11]. - The total number of shares held by the top 10 unrestricted shareholders is 100,294,266, indicating a concentration of ownership[11]. Incentive Plans and Compensation - The company has implemented a stock option and restricted stock incentive plan to promote sustainable development[15]. - The incentive plan was approved by the board and allows for stock options to be granted to eligible participants[16]. - The company completed the stock option and restricted stock incentive plan grant, awarding 18,500,000 stock options and 8,300,000 restricted shares, increasing total shares from 1,458,922,600 to 1,467,222,600[17]. - The company is in the process of terminating the 2020 stock option and restricted stock incentive plan, with ongoing procedures for the cancellation of stock options and repurchase of restricted shares[19]. - The company’s board approved the performance compensation plan for the 2020 and 2021 fiscal years, ensuring that the compensation obligations are met without further compensation required[27]. - The total compensation amount for 2020 and 2021 was 2,291,131,273.12 yuan, corresponding to 371,334,114 shares[23]. Liabilities and Financial Expenses - The total liabilities increased to CNY 5,227,597,463.85 from CNY 4,761,040,395.10 at the beginning of the year, reflecting a rise of 9.8%[32]. - Financial expenses surged by 72.91% to ¥20,521,429.99, reflecting an increase in borrowings from financial institutions[9]. - The company's short-term borrowings increased to CNY 2,051,130,000.00 from CNY 1,934,108,866.63, an increase of 6.1%[32]. Operational Costs - The total operating costs for the first quarter of 2022 were CNY 1,979,311,251.95, up 27.6% from CNY 1,551,154,489.00 in the previous year[33]. - Sales expenses increased by 39.78% to ¥897,723,939.00 due to new product launches and increased marketing activities[9].